Abstract
ABSTRACT
The absorption and distribution of radiocarbon-labeled urea at the ultratrace level were investigated with a 14C-AMS biotracer method. The radiopharmaceutical concentrations in the plasma, heart, liver, spleen, lung, kidney, stomach, brain, bladder, muscle, testis, and fat of rats after oral administration of 14C urea at ultratrace doses were determined by AMS, and the concentration-time curves in plasma and tissues and pharmacokinetic distribution data were obtained. This study provides an analytical method for the pharmacokinetic parameters and tissue distribution of exogenous urea in rats at ultratrace doses and explores the feasibility of evaluation and long-term tracking of ultratrace doses of drugs with AMS.
Publisher
Cambridge University Press (CUP)
Reference37 articles.
1. Schütz, H. 2012. Evaluation of replicate designs for (reference scaled) average bioequivalence according to FDA’s guidances with Phoenix™ WinNonlin® (2012 Pharsight, A Certara Company, Tripos L.P.).
2. radiocarbon dating using electrostatic accelerators: negative ions provide the key;Bennett;Science,1997
3. Accelerator mass spectrometry at the 4 MV Dynamitron Tandem in Bochum;Lubritto;Nuclear Instruments and Methods in Physics Research,2004
4. FDA, CDER, CBER. 2010. Guidance for Industry and Researchers: The Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application.
5. An improved method for the sealed-tube zinc graphitization of microgram carbon samples and C-14 AMS measurement;Walker;Nuclear Instruments and Methods in Physics Research, Section B. Beam Interactions with Materials and Atoms,2019